Lipocine announces patient dosed in its phase 2 study with lpcn 1148 for management of liver cirrhosis

Salt lake city, dec. 22, 2021 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed in its phase 2 proof-of-concept clinical study (nct04874350) for the management of liver cirrhosis. the phase 2 study is a multi-center, randomized, placebo-controlled 52-week study in sarcopenic cirrhotic patients that are on the liver transplant list.
LPCN Ratings Summary
LPCN Quant Ranking